Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EGFR antibody with CCRT for induction-resistant locally advanced NPC
NCT04508816Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jan 2016
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab and nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2016; status: completed.
02
Drugs
cetuximabnimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04508816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508816.